Study & follow-up of undifferentiated early arthritis
A french multicenter cohort
Primary objective

Multicenter french cohort of early arthritis for studies on:
• Diagnosis
• Prognosis
• Economic evaluation
• Pathogenesis
• Therapeutic evaluation
Inclusion criteria

- Early arthritis with possible or certain RA
- At least 2 swollen joints
- > 6 weeks, < 6 months
- No previous DMARD
- No previous steroids
- Signed consent
- Social security
Exclusion criteria

- Age < 18, > 70
- Pregnancy
- Early arthritis with diagnosis other than RA
  OR with features incompatible with RA
Specific objectives

1. **Diagnosis**
   Best combination of clinical, biologic, imaging and immunogenetic elements for diagnosis

2. **Prognosis**
   Early prognosis, determining « high-risk » profiles

3. **Economics**
   Direct and indirect costs.
Specific objectives

4. **Pathogeny**
   Constitution of a bank of serum, DNA, blood and synovial cells and synovial tissue for multiple studies: genomics, micro-arrays, auto-antibodies…

5. **Comorbidity and disability**

6. **Observation of rare events:** IRAD project.
Method

- Longitudinal prospective study: follow-up > 10 years
- 800 patients
- Inclusion period 18 months
- Follow-up: inclusion, M6, M12, M18, M24 then once a year
- Inclusion started November 14, 2002.
Recruitment

• 14 regional centers with a network of private practice rheumatologists
• 2 biology coordinating centers
• 1 national coordinating center
• National project promoted by the French Rheumatology Society (SFR) partnered by Merck (MSD) and INSERM also supported by AMGEN and ABBOTT.
Etude et Suivi des POLyarthrites Indifférenciées Récentes
Collected data

- At each visit:
  - clinical,
  - HAQ, SF 36...
  - Economic questionnaire,
  - standard biology,
  - Serum and urine samples,
  - hands and feet X Rays

- At baseline:
  Blood, DNA, blood cells, synovial cells and/or synovial tissue

- MRI/ ultrasonography protocols
Etude et Suivi des POLyarthrites Indifférenciées Récentes

Inclusions

Nb of inclusion

Inclusions réelles
Inclusions théoriques

dates

27/06/03
Préinclusions et Inclusions

Nombre de patients screenés et inclus dans chaque centre

<table>
<thead>
<tr>
<th>Centre</th>
<th>Préinclusions</th>
<th>Inclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amiens</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>Bordeaux</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>Brest</td>
<td>25</td>
<td>14</td>
</tr>
<tr>
<td>Lille</td>
<td>19</td>
<td>18</td>
</tr>
<tr>
<td>Montpellier</td>
<td>23</td>
<td>15</td>
</tr>
<tr>
<td>St Antoine</td>
<td>16</td>
<td>12</td>
</tr>
<tr>
<td>Pitié</td>
<td>11</td>
<td>8</td>
</tr>
<tr>
<td>Cochin</td>
<td>16</td>
<td>11</td>
</tr>
<tr>
<td>Bicêtre</td>
<td>52</td>
<td>21</td>
</tr>
<tr>
<td>Bichat</td>
<td>32</td>
<td>29</td>
</tr>
<tr>
<td>Rouen</td>
<td>16</td>
<td>15</td>
</tr>
<tr>
<td>Strasbourg</td>
<td>23</td>
<td>21</td>
</tr>
<tr>
<td>Toulouse</td>
<td>26</td>
<td>22</td>
</tr>
<tr>
<td>Tours</td>
<td>27</td>
<td>23</td>
</tr>
</tbody>
</table>

Date: 27/06/03
Therapeutic trials

• Therapeutic decisions will be taken by the treating private practitioners; recruitment centers will not interfere in therapeutic choices.

• BUT therapeutic trials are possible if accepted by the rheumatologists and the patients.
Scientific steering committee

• CHU Brest                           Prof. Alain SARAUX
• CHU Montpellier                     Prof. Bernard COMBE
• CHU Nancy                           Prof. Francis GUILLEMIN
• CHU Paris Bichat                     Prof. Philippe RAVAUD
• CHU Paris Cochin                     Prof. Maxime DOUGADOS
• CHU Paris Pitié-Salpétrie            Dr. Bruno FAUTREL
• CHU Rouen                           Prof. Xavier LE LOËT
• CHU Strasbourg                       Prof. Jean SIBILIA
• CHU Toulouse                         Prof. Alain CANTAGREL
• MSD laboratory                       Dr. Isabelle LOGEART